• 1605: Who and What Is Missing from the Hepatitis C Treatment Cascade of Care?

    (A report back from presentation by Dr Sione Crawford, CEO, Harm Reduction Victoria, Australia)

    “Cascade of Care” has been an often repeated phrase in the last few days.   It is a useful concept which describes the steps across the continuity of care in the treatment of chronic hepatitis C (CHC), and estimates the number of people with chronic hepatitis C engaging in each successive step.  Typically, the steps in a CHC cascade are: people with CHC, people diagnosed with CHC, people undergoing treatment, people who have achieved a cure.   We have been extremely encouraged to see a dramatic increase in the numbers of people in treatment since the advent of directly acting antivirals in Australia in March 2016. 

    Continue reading…

  • Simplifying Diagnosis and Treatment for Hepatitis B & C – Now and into the Future (Science & Clinical Care Theme)

    This session was presented by several speakers with the aim of familiarising attendees with the key challenges to simplifying testing and treatment for HCV and HBV. 

    Presented by:  Tanya Applegate, Jane Davies, Amanda Wade, David Anderson 

    Continue reading…

  • Global to Local: Finding the Missing Millions to Whole-Person Health

    (A report back on the presentation of Dr Michael Ninburg - Global to Local. Finding the Missing Millions to Whole-Person Health)


    This presentation by Michael Ninburg, the President of the World Hepatitis Alliance, was a fascinating overview of the rise of viral hepatitis to the international stage, and a reminder that all solutions for population wide scale-up of hepatitis B and C treatments must be patient-led and locally driven. 

    Continue reading…

  • No One Left Behind? the Role of Social Policy in Viral Hepatitis

    (A report back from Dr Kylie Valentine - No one left behind? The role of social policy in viral hepatitis - the Australasian Viral Hepatitis Conference)

    Kylie had a fascinating talk outlining the role of social policy in viral hepatitis. She determines social policy as society’s responses to “big picture” questions of how best to distribute resources through taxation, income support, programs and services. Social policies outline what a society regards as important and fixable problems, what those problems are and thought to be, and what is not a priority. Social policy research tells us about how different groups of people are affected by these choices and priorities, and how policies and policy domains interact.

    Continue reading…

  • Leave Judgement at the Door

    (A report back from lived experience speakers)

    The rapid developments in Hepatitis C management since direct acting antiviral therapy became available on the pharmaceutical benefits scheme in March 2016 has been nothing short of amazing. Now with the advent of pan genotypic regimes and comparative treatment success regardless of the presence of cirrhosis, Australia is a privileged and unique position to ensure no one is left behind in its pursuit of Hepatitis C eradication by 2030. Despite this, achieving this target remains ambitious given the stigma associated with a Hepatitis C diagnosis.

    Continue reading…

  • Testing, Treating and Cancer Screening

    A report back from Dr Sunil Solomon - Elimination of hepatitis C in people who inject drugs in low and middle income countries: The Final Frontier; Dr Joseph Doyle - Australian Hepatitis Elimination Scorecard: Progress since the Australasian Viral Hepatitis Elimination Conference - The Australasian Viral Hepatitis Conference Opening Plenary 


    As a GP based in Lakes Entrance I provide care to rural and remote areas. Chronic disease management is a major part of the day-to-day work this involves.  Attending the 11th Australasian Viral Hepatitis Conference produced many lightbulb moments – most notably that some of these diseases are treatable and even curable, as in the case of Hepatitis C.  The two main challenges remain engaging those we know have Viral Hepatitis in treatment and finding those who do not yet know they have Viral Hepatitis. The awareness of chronic infection is relevant both for the new phase of safe and effective cures available for Hepatitis C, and the risks of ignorance of chronic Hepatitis B infection. 

    Continue reading…

  • What Social Policy Can Tell Us About Viral Hepatitis?

    (A report back on A/Professor Kylie Valentine - No one left behind? The role of social policy in viral hepatitis - Australasian Viral Hepatitis Conference Day 1 )

    What social policy can tell us about viral hepatitis? 

    Social Policies are society’s responses to ‘big picture’ questions of how best to distribute resources through taxation, income support, programs and service. 

    Continue reading…

  • Avoiding Unnecessary Testing - Removing Barriers for Hepatitis C Treatment

    (A report back from Dr Sunil Solomon - Elimination of hepatitis C in people who inject drugs in low and middle income countries: The Final Frontier - The Australasian Viral Hepatitis Conference Day 1)

    I really enjoyed Dr Sunil Solomon’s presentation. It was about how GPs can do case finding by finger prick test and confirm Hepatitis C by a blood test. Dr Sunil spoke about avoiding unnecessary testing pre-treatment and during follow up after starting treatment to reduce obstacles for patients and help to achieve the goal of eliminating hepatitis C. 



    Continue reading…

  • Opening Plenary - the 11th Australian Viral Hepatitis Conference

    (A report back on the Australasian Viral Hepatitis Conference Day 1)

    There were a number of interesting topics presented during the opening plenary of the 11th Australian Viral Hepatitis conference.

    Continue reading…

  • HCV Among People Who Inject Drugs in Australia

    This informative session was presented by Jenny Iverson from The Kirby who oversees the Australian Needle Syringe Program Survey (ANSPS). Click here for the abstract. 

    The ANSPS has been run annually since 1995 and consists of a self directed questionnaire as well as a dried blood spot (DBS) for HIV & HCV antibody testing. The survey has approximately 2000-2500 respondents yearly, with about 75% of participants residing in metropolitan areas. A number of needle and syringe program (NSP) sites are involved.  

    Continue reading…